Sponsor hub
Jazz Pharmaceuticals clinical trial failures
Review 36 stopped clinical trials from Jazz Pharmaceuticals, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 3 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 22
- OTHER/UNKNOWN
- 11
- SAFETY
- 2
- EFFICACY/FUTILITY
- 1
Notable sponsors
- Jazz Pharmaceuticals
- 36
Related phases
- Phase II
- 20
- Phase III
- 9
- Phase I
- 6
- Phase IV
- 1
Crawlable stopped-trial records
Open ExploreShowing up to 36 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I Narcolepsy trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The study was terminated based on a business decision by the Sponsor.
Phase III Seizure in Participants With Tuberous Sclerosis Complex trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The study was terminated by the Sponsor due to low patient enrollment.
Phase II Glioma trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201).
Phase II Advanced Solid Tumor trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
Termination of this study was a business decision made during portfolio review.
Phase I Diffuse Intrinsic Pontine Glioma trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201).
Phase III Seizures Associated With EMAS trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The study was terminated due to a business decision.
Phase II Glioblastoma trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201).
Phase II Endometrial Cancer Recurrent trial by Jazz Pharmaceuticals. Stop reason: SAFETY.
This study was terminated due to a change in the Sponsor's corporate priorities. The decision to terminate the study was not based on any safety concerns.
Phase III Spasticity With Multiple Sclerosis trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The study was terminated based on a business decision by the Sponsor.
Phase II Irritability Associated With Autism Spectrum Disorder trial by Jazz Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
A decision has been made to prioritize other pipeline programs and terminate this study.
Phase I Multiple Myeloma trial by Jazz Pharmaceuticals. Stop reason: SAFETY.
This study was terminated due to a change in corporate priorities. The decision to terminate the study was not based on any safety concerns.
Phase I Advanced Solid Tumor trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The study was terminated based on a business decision by the Sponsor.
Phase III Multiple Sclerosis (MS) trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
This study was terminated based on a business decision by the Sponsor.
Phase III Acute Myeloid Leukemia trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
Study enrollment was terminated on 16 May 2022 due to slow recruitment.
Phase II Schizophrenia trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
This study was terminated based on a business decision by the Sponsor.
Phase II Autism Spectrum Disorder trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
Study terminated due to enrollment challenges during COVID-19 pandemic.
Phase III Rett Syndrome trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The study was terminated due to enrollment challenges and the COVID-19 pandemic.
Phase IV Lennox-Gastaut Syndrome trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The decision to withdraw the study was based on pandemic-related concerns of conducting a Phase IV study requiring multiple clinic visits when medication is commercially available. The study was withdrawn before any participants were recruited.
Phase II Coronavirus Disease 2019 (COVID-19) trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
Due to improvement in the Coronavirus Disease 2019 (COVID-19) pandemic and low subject accrual.
Phase III Rett Syndrome trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
Study was terminated due to COVID-19 pandemic and recruitment challenges in the parent study (GWND18064 - NCT03848832).
Phase II Metastatic Pancreatic Cancer trial by Jazz Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Post-Traumatic Stress Disorder trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The decision to suspend this study was based upon evaluation of pandemic-related challenges impacting both clinical trial sites and potential participants. This suspension was initiated prior to site activation and participant recruitment.
Phase II DLBCL trial by Jazz Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
Primary endpoint would unlikely to be met based on the unplanned interim assessment on the first 20 efficacy evaluable patients.
Phase II Chronic Obstructive Pulmonary Disease trial by Jazz Pharmaceuticals. Stop reason: EFFICACY/FUTILITY.
Interim analysis: safety without efficacy ODSH in patients with acute COPD.
Phase I Protein Losing Enteropathy trial by Jazz Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
Extremely slow accural due to rarity of medical condition studied.
Phase II Adenovirus trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
terminated due to low enrollment rate
Phase III Cytomegalovirus Disease trial by Jazz Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
Study terminated early due to results from another CMX001 study.
Phase III Cytomegalovirus Disease trial by Jazz Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
Study was terminated early due to results from another CMX001 study
Phase II Parkinson's Disease trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
The program was not initiated nor were any patients ever enrolled. The investigations detailed in the submitted protocol were incorporated into another program.
Phase I Advanced Glioblastoma trial by Jazz Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
Protocol not activated.
Phase II Adenovirus trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
terminated due to low enrollment rate
Phase II Ebola Virus Disease trial by Jazz Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Acute Myeloid Leukemia (AML) trial by Jazz Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Acute Lymphoblastic Leukemia trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.
Sponsor decision
Phase II Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) trial by Jazz Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Ebola Virus trial by Jazz Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
Suspended Development Program